Steve is an experienced technical Pharmaceutical and Biotech recruitment executive for which he has been completely embedded into the rare diseases and advanced therapies communities since 2017.
His core expertise is highly technical and strategic candidate sourcing and management within heavily restricted market sectors. He was previously Head of Rare Diseases and Cell & Gene Therapy Executive Search at both Next Phase Recruitment and Morgan Prestwich.
At the beginning of his career, Steve spent 9 years with Barrington James during their expansion from a single, 14-person UK-based pharma recruitment agency to the world’s largest pharma recruiter spanning all major continents.
His other roles have included 5 years as Recruitment Excellence Training Manager within Barrington James’ Headquarters as well as secondments and support roles in sales, managerial and training remits within the Singapore and Malaysian offices.
Mark brings over 30 years’ experience in the life sciences and financial sectors within both global organisations and early-stage companies including advanced therapies and rare diseases Biotechs and major consulting outfits such as Goldman Sachs, KPMG, McKinsey & Co and Charles River Labs.
His Biotech appointments include the role of Corporate Development Director, then Group Chief Financial Officer and Executive Board Member, of Celixir plc, a clinical stage biotechnology company focused on developing cellular regenerative therapies, Non-Executive Chair of AMPLY Discovery, an early-stage biotechnology company harnessing the power of A.I. to discover new therapies for cancer and multi-drug resistant infections, Chief Executive Officer at Sutura Therapeutics, a pre-clinical gene medicine company where he built the board in support of a subsequent seed raise of £11m and CEO at UTILITY therapeutics.
He has led multiple successful licensing deals, both on the buy side and sell side, and has raised a total $40M in seed and Series A funding to-date.
He brings additional detailed understanding of the life sciences industry from his roles in sales, marketing, business development and R&D whilst at Abbott Laboratories and GlaxoSmithKline.
Mark holds a BA (Hons) and MA in Mathematics from The Queen’s College, Oxford University, and is a fully qualified Chartered Management Accountant
